MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that its corporate presentation will be webcast live during the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 9:00 a.m. Eastern Time. The presentation will be webcast from The New York Palace Hotel in New York and will be presented by Thomas B. King, Alexza President and CEO.
A replay of the Webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.
AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.
AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.
Alexza Pharmaceuticals, Inc.
